ETX — E-Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- £58.58m
- £27.19m
- £0.48m
2019 January 31st | 2020 January 31st | R2021 January 31st | 2022 January 31st | 2023 January 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -4 | -2.35 | -3.68 | -8.07 | -8.27 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | -1.04 | -0.526 | -0.397 | -1.04 | -1.82 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 1.29 | 0.749 | 0.612 | 1.1 | 1.62 |
Change in Accounts Receivable | |||||
Change in Payable / Accrued Expenses | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -3.7 | -2.03 | -3.36 | -7.8 | -8.01 |
Capital Expenditures | -0.028 | -0.016 | -0.071 | -0.963 | -0.21 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 2.53 | 0.015 | -5 | -8.98 | 15.5 |
Change in Net Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 2.5 | -0.001 | -5.07 | -9.94 | 15.3 |
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 0.011 | -0.035 | 12.6 | 22.3 | 13 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -1.19 | -2.06 | 4.17 | 4.59 | 20.3 |